Mithra Pharmaceuticals Overview
Mithra was a Belgian specialty-pharma and biotech company built around a single scientific bet: estetrol (E4), a native oestrogen produced by the human foetal liver, which Mithra argued offered a more selective, safer and environmentally friendlier hormonal profile than ethinylestradiol or estradiol. It converted that bet into one approved product — the combined oral contraceptive Estelle (E4/drospirenone, sold as Nextstellis in the US and Drovelis/Lydisilka in Europe) — and one late-stage asset, Donesta (E4 monotherapy for menopausal vasomotor symptoms). Around that core it operated a generics and complex-therapeutics business (Novalon: Myring, Tibelia, Daphne, Zoreline) and a 2017-vintage GMP manufacturing plant (Mithra CDMO, Flémalle). The science largely succeeded; the capital structure did not. Weak Estelle uptake, a cash-hungry CDMO, heavy convertible debt and dilutive financing led to insolvency in June 2024. Its crown jewels now belong to Gedeon Richter, which won EU approval for Donesta (as Fylrevy) in March 2026.
Company's own description (last "About Mithra" boilerplate, 2024 press releases, paraphrased). Mithra described itself as a Belgian biopharmaceutical company dedicated to women's health, aiming to develop products with better efficacy, safety and convenience. It explored estetrol across a broad range of applications, having launched the first estetrol-based product, the contraceptive pill Estelle, in 2021, and was focusing on Donesta as a next-generation hormone therapy. It also offered partners a full spectrum of services — early development, clinical batches and commercial manufacturing of complex polymeric products (vaginal rings, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes, cartridges) — through its Mithra CDMO platform.
Business model. Mithra was fundamentally an out-licensing model: it carried E4 products through development and regulatory approval, then licensed commercial rights territory by territory to partners (Mayne Pharma in the US, Gedeon Richter in Europe/Russia/CIS, Fuji Pharma in Japan, and numerous smaller regional partners), collecting upfront payments, regulatory/commercial milestones, and supply revenues (Mithra manufactured or arranged manufacture and sold finished product to licensees). Royalty-like economics came through supply pricing and sales milestones.
Revenue model mix (FY2023, EUR 40.2M total, per FY2023 results release of 8 March 2024).
Note: sub-lines of product sales (10.4 + 8.1 = 18.5) differ slightly from the 18.7 total; the residual is not itemised in the release.
Value chain position. Upstream: proprietary E4 active pharmaceutical ingredient process (including a novel manufacturing process proof-of-concept with University of Liège announced in 2023); midstream: clinical development and regulatory filings; downstream: supply of finished goods to licensees, plus third-party contract manufacturing. Mithra did not field its own large sales force in major markets.
Customer types. Pharmaceutical licensees (primary), wholesalers/distributors for Novalon generics in Benelux and selected markets, and third-party pharma/biotech clients for CDMO services.
End-markets. Hormonal contraception; menopause hormone therapy (HT/HRT); generic women's health products (vaginal ring, tibolone, oral contraceptives); oncology hormone therapy (Zoreline, a goserelin implant candidate); contract manufacturing.
Independent characterisation. Mithra was a single-molecule platform company with an over-built industrial base. Its revenue was lumpy and milestone-driven (FY2019's record EUR 96.5M and FY2022's EUR 67.0M were both deal-driven, not recurring), while its cost base — clinical programmes for Donesta and a CDMO running at a deficit the chairman put at EUR 30–35M per year — was recurring. The company financed the gap with equity placements, convertible bonds and a share-subscription facility (LDA Capital), producing a dilution spiral that collapsed the share price from above EUR 35 (2018) to about EUR 0.22 (early 2024).
Strategy
Pre-crisis strategy (2021–2023, from results releases). Mithra's stated themes were: (1) maximise Estelle's global roll-out through partners; (2) bring Donesta to market in the US (target H1 2024) and EU (H1 2025) and sign a US Donesta licence; (3) refocus R&D spending on Donesta and Estelle, pausing or discontinuing non-core projects (2023); (4) find a strategic solution for the "underexploited" CDMO; (5) extend runway through non-dilutive deals, receivables monetisation and asset sales.
24-month initiatives register (Oct 2022 – Jun 2024).
ESG commitments. Mithra promoted E4 as environmentally friendlier than ethinylestradiol and described its new E4 process as lower-footprint. No formal emissions targets identified.
Medium-term targets. Last guidance: Estelle product sales EUR 8.5M for FY2023 (beaten at EUR 10.4M). No current guidance exists.
Products & Services
Estetrol (E4) franchise (sold to Gedeon Richter, June 2024)
Estelle (E4 15 mg / drospirenone 3 mg combined oral contraceptive).
-
Brands: Nextstellis (US, Mayne Pharma; Canada), Drovelis and Lydisilka (Europe, Gedeon Richter and partners), other regional brands via Fuji (Japan) and others.
-
Approval: FDA 15 April 2021; EU 2021; Canada and Russia 2021.
-
Positioning: first new oestrogen in a combined oral contraceptive in decades; claimed favourable haemostatic and metabolic profile versus ethinylestradiol-based pills and lower environmental persistence.
-
Commercial performance: Mithra product sales of EUR 9.2M (FY2022) and EUR 10.4M (FY2023), beating September 2023 guidance of EUR 8.5M; H1 2023 sales EUR 2.6M. These figures represent Mithra's supply sales to partners, not end-market sales.
-
Lifecycle: paediatric study in more than 100 adolescents aged 12–17 completed in 2023.
-
Pricing model: supply price to licensees plus milestones; consumer pricing set by licensees (NPD).
Donesta (E4 monotherapy for menopause; now Fylrevy).
-
Indication: moderate to severe vasomotor symptoms (VMS) and oestrogen-deficiency symptoms in postmenopausal women.
-
Clinical: E4 Comfort I/II Phase III programme; positive efficacy topline (January 2022); positive North American safety topline (March 2023); positive DSMB review.
-
Doses tested: 15 mg and 20 mg (Mithra); approved EU strengths 14.2 mg and 18.9 mg estetrol film-coated tablets (expressed differently, likely anhydrous vs monohydrate basis).
-
Regulatory: Mithra originally targeted US approval in H1 2024 and EU in H1 2025; FDA feedback on the NDA was received in 2023. Under Richter, CHMP positive opinion 29 January 2026 and EC approval 27 March 2026; launch expected from H2 2026. US regulatory status under new ownership: not publicly confirmed in sources reviewed.
-
Licensing: Richter licence (~90 territories, Europe, Russia/CIS, Latin America, Australia/NZ) with EUR 55M upfront; Richter China rights (EUR 2.5M recognised FY2023). Mithra expected to sign a US Donesta deal in 2024; none was announced.
Other E4 programmes. Coronesta (E4 for COVID-19 patients; results expected H2 2021, no further development disclosed); earlier E4 research in neonatal encephalopathy and other indications (Neuralis); these were largely paused when Mithra refocused on Donesta and Estelle in 2023.
Novalon complex therapeutics and generics (judicial reorganisation)
| Product | Description | Notes |
|---|---|---|
| Myring | Etonogestrel/ethinylestradiol contraceptive vaginal ring (generic to NuvaRing) | Launched 2020 in several markets; H1 2023 sales EUR 2.4M; produced at CDMO (capacity cited near 7 million rings per year) |
| Tibelia | Tibolone (menopause) generic | Part of EUR 8.1M FY2023 Novalon generics sales |
| Daphne | Oral contraceptive generic | Part of Novalon generics |
| Zoreline | Goserelin biodegradable implant (prostate/breast cancer) candidate | Full rights acquired 2021; EUR 26.4M impairment in FY2023 |
Mithra CDMO services (bankrupt; site sold to Trasis)
-
Polymeric technologies: vaginal rings, implants (hot-melt extrusion).
-
Injectables: complex liquid injectables and biologicals in vials, pre-filled syringes and cartridges.
-
Services: early development, clinical batch manufacturing, commercial manufacturing.
-
Revenue: R&D contracting EUR 2.4M in both FY2022 and FY2023 — trivially small against the plant's cost base. EUR 47.7M impairment in FY2023.
Financial Narrative
Five most recent reported fiscal years: FY2019–FY2023. No financial statements exist for FY2024 or later. Sources: annual results releases dated 9 March 2020, 9 March 2021, 8 March 2022, 7 March 2023 and 8 March 2024; FY2023 balance-sheet aggregates from Google Finance (aggregator, flagged).
Income statement
Notes: FY2019 EBITDA later restated to 32.7. FY2020 EBITDA shown as -73.8 in the FY2021 comparative. Gross profit, operating income and pre-tax income are reported in the full statements but were not verifiable from sources reviewed. FY2023 EBITDA not stated in the sourced extracts. Revenue CAGR FY2019–FY2023: approximately -20% per year (96.5 to 40.2), distorted by the FY2019 milestone peak; FY2020–FY2023 CAGR approximately +64%.
Commentary. Mithra's P&L was dominated by licensing timing. FY2019 was flattered by the Mayne Pharma US Estelle deal; FY2020 collapsed to EUR 9.0M as no comparable deal landed and Estelle had not yet launched. FY2021 recovered with first Estelle deliveries (EUR 13.4M product sales) but EBITDA stayed deeply negative (EUR -77.5M) on Donesta Phase III spending. FY2022 revenue of EUR 67.0M was driven by the EUR 55M Richter Donesta upfront; strip that out and underlying revenue was roughly EUR 12M. FY2023 revenue of EUR 40.2M included EUR 19.0M of out-licensing; the EUR 173.5M net loss was swollen by EUR 74.1M of impairments (CDMO EUR 47.7M, Zoreline EUR 26.4M). The core structural problem: recurring product sales never exceeded about EUR 19M, against an operating cost base that, including the CDMO, ran near EUR 100M.
Balance sheet
Notes: FY2023 total assets, liabilities and equity from aggregator data (Google Finance); FY2023 total assets also appear in a third-party filings index as EUR 286.55M "per the Earnings Release filed 2024-03-08". Total debt split, net debt, goodwill and intangibles, and working capital: NPD from sources reviewed. Indicatively, with ~EUR 390M liabilities and EUR 9M cash at end-2023, net liabilities exceeded EUR 100M.
Commentary. Equity eroded from EUR 163M (FY2019) to EUR 34M (FY2021) to negative ~EUR 103M (FY2023). The EUR 138M cash peak at end-2020 reflected the EUR 125M convertible and EUR 65M placement; it was consumed within three years. In 2022 Mithra repurchased EUR 34.1M of the 2025 convertibles at a discount using new money from the same holders — a sign the capital structure was already stressed.
Cash flow and financing
Notes: FY2023 operating and free cash flow from aggregator data and appear inconsistent with the EUR 19.3M decline in cash; treat as unreliable. FY2023 equity raised = Armistice EUR 18.4M + Highbridge/Whitebox EUR 2.5M + loan conversion EUR 1.2M + contributions in kind for interest EUR 3.5M. FY2022 capital increases EUR 77.0M net. Cash collection from out-licensing milestones was EUR 56.4M in FY2023.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Legal Entity Details
| Legal entity | Function | Fate |
|---|---|---|
Mithra Pharmaceuticals SA | Listed parent, Liège | Bankrupt 10 June 2024 |
Estetra SRL | E4 product rights and commercial/licensing hub (Estelle, Donesta) | Sold to Gedeon Richter, June 2024 |
Neuralis SA | E4-related entity (neuroscience/other E4 applications) | Sold to Gedeon Richter, June 2024 |
Mithra R&D SA | R&D; held estetrol manufacturing assets | Estetrol manufacturing assets sold to Richter, June 2024; remainder NPD |
Novalon SA | Complex therapeutics and generics (Myring, Tibelia, Daphne, Zoreline) | Judicial reorganisation from April 2024; final outcome NPD |
Mithra Pharmaceuticals CDMO SA | Flémalle contract manufacturing plant | Bankrupt July 2024; site sold to Trasis, May 2026 |
Revenue Lines
| Revenue line (EUR Mn) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Total revenue | 22.7 | 67.0 | 40.2 |
Product sales (total) | 13.4 | 15.7 | 18.7 |
Estelle product sales | — | 9.2 | 10.4 |
Novalon generics sales | — | — | 8.1 |
CDMO R&D contracting revenue | — | 2.4 | 2.4 |
Out-licensing revenue | — | — | 19.0 |
Segment Margins & Growth (%)
| Metric | FY2022 vs FY2021 | FY2023 vs FY2022 |
|---|---|---|
Total revenue growth | +195% | -40% |
Product sales growth | +17% | +19% |
Estelle product sales growth | NPD | +13% |
Product sales as % of revenue | 23% | 47% |
Income Statement and Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 96.5 | 9.0 | 22.7 | 67.0 | 40.2 |
Revenue YoY growth (%) | 47 | -91 | 152 | 195 | -40 |
EBITDA (EUR Mn) | 40.7 | -73.0 | -77.5 | -14.3 | — |
Net income (EUR Mn) | -26.6 | — | -116.9 | -59.6 | -173.5 |
Total comprehensive loss (EUR Mn) | — | — | -134.2 | -77.9 | -167.1 |
EPS basic (EUR) | — | — | -2.63 | — | — |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
EBITDA margin (%) | 42 | — | — | -21 | — |
Net margin (%) | -28 | — | -515 | -89 | -432 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash and equivalents (EUR Mn) | 49 | 138 | 32.9 | 28.3 | 9.0 |
Total equity (EUR Mn) | 163.3 | 157.7 | 33.8 | — | -103.3 |
Total assets (EUR Mn) | — | — | — | — | 286.6 |
Total liabilities (EUR Mn) | — | — | — | — | 389.8 |
Estelle earnout liability, fair value (EUR Mn) | — | 115.7 | 110.0 | — | — |
Convertible bonds due 2025, issued (EUR Mn) | — | 125 | — | — | — |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash flow (EUR Mn) | — | — | — | — | -8.2 |
Free cash flow (EUR Mn) | — | — | — | — | -3.0 |
Equity raised, net (EUR Mn) | — | 65 | — | 77.0 | 25.6 |
Dividends paid (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
ROE | Deeply negative (net loss 116.9 on equity 33.8) | Negative | Not meaningful (negative equity) |
ROA | NPD | NPD | Approx. -61% (net loss 173.5 / assets 286.6) |
Current ratio | NPD | NPD | NPD (going-concern doubt) |
Debt/equity | NPD | NPD | Not meaningful |
Net debt/EBITDA | Not meaningful (negative EBITDA) | Not meaningful | Not meaningful |
Interest coverage | Negative | Negative | Negative |
Asset turnover | NPD | NPD | ~0.14x |
Cash conversion cycle | NPD | NPD | NPD |
Region (By Licensee Geography) Overview
| Region (by licensee geography) | Principal revenue sources | Disclosure |
|---|---|---|
North America | Mayne Pharma (Nextstellis US), Canadian partner; supply sales and milestones | Amount NPD |
Europe / Russia / CIS | Gedeon Richter (Drovelis, Donesta upfront EUR 55M in FY2022); Novalon generics in Benelux | Amount NPD |
Asia-Pacific | Fuji Pharma (Japan; EUR 10.0M recognised FY2023, EUR 1.25M and EUR 2.5M milestones in 2023); Mayne Pharma (Australia launch 2022); Richter China (EUR 2.5M FY2023); Hong Kong/Taiwan partners | Partial |
Latin America, South Africa | Regional Estelle licensees signed 2020 | Amount NPD |
Region revenue (EUR Mn) | FY2021 | FY2022 |
Capital Markets
| Metric | Detail |
|---|---|
Share price history | Above EUR 35 (2018); ~EUR 23.2 (Mar 2021); ~EUR 18.0 (Sep 2021); ~EUR 13.9 (Mar 2022); ~EUR 6.7 (Sep 2022); ~EUR 3.1 (Mar 2023); ~EUR 2.1 (Sep 2023); ~EUR 1.52 (Jul 2023 Test-Achats); ~EUR 0.22 (early 2024) |
1-year / 3-year / 5-year return | Not applicable (suspended 29 Apr 2024); effectively -100% for all horizons |
Analyst consensus | None current; Test-Achats/Test-Aankoop moved to hold in 2023 |
Dividends | Never paid |
Buybacks | None; EUR 34.1M convertible bond repurchase (2022) |
Credit ratings | No Moody's/S&P/Fitch ratings |
Debt maturity profile | EUR 125M convertibles due 2025 (partly repurchased); LDA facility to April 2025; secured loans and bridge facilities — all subsumed in bankruptcy |
Share price reference (EUR) | FY2020 |
Approximate price at results date (Mar following year) | 23.2 |
Analyst Conclusions
Management guidance. None. The company is in bankruptcy; no management exists in an operating sense, and trustees control residual matters.
Consensus expectations. None. There is no equity to value.
Bull-case arguments (for any residual stakeholder, i.e., creditors).
-
The EUR 175M Richter proceeds provided a substantial pool for creditors after financial debts.
-
The 2026 Trasis acquisition converted an idle plant into realisable value for CDMO creditors.
-
Novalon's restructuring may yield further recoveries.
Bear-case arguments.
-
Shareholders recover nothing; the company stated explicitly that the Richter sale created no shareholder value.
-
Unsecured creditor recoveries are likely partial given ~EUR 390M liabilities at end-2023.
-
Bankruptcy distributions in Belgium can take years, and claims litigation may delay them.
Monitorables (next 12 months).
-
Parent bankruptcy distributions and closure timing.
-
Novalon restructuring outcome.
-
Outcome of former-CEO and founder-related litigation.
-
Gedeon Richter's EU launch of Fylrevy (H2 2026) and any US filing — relevant as validation of Mithra's science, not value to Mithra holders.
-
Trasis Flémalle start-up (targeted early 2027).
Analyst verdict. Mithra Pharmaceuticals is a case study in a scientific success wrapped in a financial failure. The company's core thesis — that estetrol is a clinically meaningful and safer oestrogen — has been vindicated by regulators twice: FDA and EU approval of Estelle in 2021 and European Commission approval of Donesta as Fylrevy in March 2026. Yet the listed company did not survive to capture that value. The causes are visible in the numbers. Recurring product sales never exceeded about EUR 19M a year, while R&D ran at EUR 57–77M and the Flémalle CDMO consumed an estimated EUR 30–35M annually with only EUR 2.4M of contract revenue. Revenue depended on lumpy milestones — EUR 96.5M in FY2019, EUR 9.0M in FY2020 — that could not fund a fixed cost base. Management financed the gap with convertible bonds, secured loans, an equity-line facility and repeated placements, each more dilutive than the last, until equity turned negative (about EUR -103M at end-2023) and cash fell to EUR 6.5M in February 2024. Governance instability — the founder's legal troubles, three CEOs in four years and an abrupt CEO termination — compounded investor distrust. The final outcome distributed the franchise efficiently: Gedeon Richter, the natural owner, bought the E4 business for EUR 175M, and Trasis repurposed the plant. For equity investors, the result was total loss. For the industry, the lesson is that small-cap platform companies should not vertically integrate into manufacturing before commercial scale is proven, and that partner-dependent launches in generic-heavy markets ramp far more slowly than licensing models assume. Mithra as an investable entity no longer exists; any analysis going forward belongs to Gedeon Richter's estetrol franchise, not to MITRA.BR.
Sources consulted (primary and secondary)
-
Mithra press releases: FY2019 results (9 Mar 2020); H1 2020 results; FY2020 results (9 Mar 2021); 2020 Annual Report; H1 2021 results (24 Sep 2021); FY2021 results (8 Mar 2022); FY2022 results (7 Mar 2023); FY2023 results (8 Mar 2024); cash update (6 Feb 2024); Mayne share sale (15 Feb 2024); monetisation updates (5 Mar, 28 Mar, 29 Apr, 4 Jun 2024); bankruptcy (10 Jun 2024); Richter sale (11 Jun 2024)
-
FSMA trading suspension notice (18 Jun 2020)
-
EMA CHMP summary of opinion, Fylrevy (29 Jan 2026); Gedeon Richter EC approval announcement (27 Mar 2026)
-
Trasis press release and Belgian press on Flémalle acquisition (May 2026)
-
La Libre Belgique, RTBF, Belga, Brussels Times, L-Post, Pharmaceutical Technology, Test-Achats/Test-Aankoop, Flanders.bio, Infostart (Hungary)
-
Aggregators (flagged where used): Google Finance, Simply Wall St, Yahoo Finance, financialfilings.com, zavia.ai
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background |
|---|---|---|---|
Christophe Maréchal | Co-CEO (from 5 March 2024); previously CFO | CFO since early 2017 | Finance; age and education NPD |
Xavier Paoli | Co-CEO (from 5 March 2024); previously COO | COO since September 2023 | Operations/commercial; details NPD |
Graham Dixon | Chief Scientific Officer (2023) | NPD | Led Donesta programme |
Executive Leadership Team — François Fornieri
| Name | Period | Context |
|---|---|---|
François Fornieri | 1999 – 2020 | Co-founder; stepped back in 2020 amid judicial proceedings; retained ~18% stake and a reported EUR 40,000/month advisory fee (La Libre, March 2023) |
Leon Van Rompay | 2020 – 2023 | Led Estelle approvals/launch and Richter Donesta deal |
David Horn Solomon | 2023 – 5 March 2024 | Management agreement terminated after less than a year; announced legal claims for compensation in April 2024 |
Major Shareholders
| Holder | Stake | Source/date |
|---|---|---|
François Fornieri (directly/indirectly) | ~18% | CEO statement, March 2023 |
Armistice Capital LLC | NPD (EUR 20M placement, Aug 2023) | FY2023 results |
Highbridge Capital / Whitebox Advisors | Equity stakes NPD; major secured creditors and convertible holders | La Libre, Sept 2024 |
LDA Capital | Share-subscription facility counterparty | FY2022 results |
Free float / retail | Majority, heavily retail Belgian base | Press coverage |
Competitive Landscape
Key Competitors
| Competitor | Relevant products | Positioning vs Mithra |
|---|---|---|
Bayer | Yaz/Yasmin (drospirenone/EE), Qlaira | Market leader in OCs; Estelle shares the drospirenone progestin |
Organon | NuvaRing, Nexplanon | Ring incumbent vs Myring generic |
Exeltis (Insud Pharma) | Slynd (drospirenone-only pill) | Novel-pill competitor in US |
Gedeon Richter | Broad women's health portfolio | Partner, then acquirer |
Viatris, Teva, Lupin | Generic OCs and rings | Price competition for Novalon |
Evofem | Phexxi (non-hormonal) | Alternative modality |
Astellas | Veozah (fezolinetant, non-hormonal NK3 antagonist) | Major new non-hormonal VMS option |
Bayer | Elinzanetant (Lynkuet), non-hormonal | Non-hormonal VMS entrant |
Pfizer | Premarin, Duavee | Hormone therapy incumbent |
Mayne Pharma / TherapeuticsMD | Bijuva (estradiol/progesterone) | Hormonal HT |
Besins | Estrogel, Utrogestan | Transdermal/body-identical HT |
Peer Comparison FY2023
| Metric | Mithra (FY2023) | Gedeon Richter | Bayer | Organon |
|---|---|---|---|---|
Revenue | EUR 40.2M | Multi-billion (verify) | Tens of billions EUR (verify) | ~USD 6bn (verify) |
Growth | -40% | NPD here | NPD here | NPD here |
Net margin | -432% | Profitable | NPD here | Profitable |
R&D intensity |
| NPD here | NPD here | NPD here |
Recent Developments
As the listed company ceased operating in mid-2024, the register covers the final collapse and subsequent asset outcomes through October 2026.



